Urban economics

DGAP-News: Deutsche Postbank Funding Trust III announces the Netherlands as its home member state

Retrieved on: 
Monday, August 29, 2022

Deutsche Postbank Funding Trust III announces that it has notified the Dutch Authority for the Financial Markets that as of 15 July 2022 the Netherlands is its home Member State for purposes of the EU Transparency Directive.

Key Points: 
  • Deutsche Postbank Funding Trust III announces that it has notified the Dutch Authority for the Financial Markets that as of 15 July 2022 the Netherlands is its home Member State for purposes of the EU Transparency Directive.
  • The EU Transparency Directive applies to Deutsche Postbank Funding Trust III as a foreign issuer with securities admitted to listing and to trading on a regulated market in the European Economic Area and the home Member State notification is a consequence thereof.
  • The issuer is solely responsible for the content of this announcement.
  • The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Terraoil Prepares New Corporate Structure

Retrieved on: 
Monday, August 22, 2022

The new structure involves the establishment of a new holding company (Topco) in which all shareholders will be provided the opportunity to exchange their shares in Terraoil Swiss AG (TOS) for shares in Topco.

Key Points: 
  • The new structure involves the establishment of a new holding company (Topco) in which all shareholders will be provided the opportunity to exchange their shares in Terraoil Swiss AG (TOS) for shares in Topco.
  • The new structure will provide benefits to Swiss and international investors which we believe will assist the Company in realizing its financial and operational objectives.
  • If you are an Terraoil shareholder and would like additional information, contact Peter Krempin either via email [email protected] or by telephone at +41 71 544 01 20.
  • The forward-looking statements contained in this media release are based on the views and assumptions of Terraoil Swiss AG as of this date and Terraoil Swiss AG does not assume any obligation to update or revise this media release.

TERRAOIL SWISS AG: Terraoil Provides Update on Next Shareholders’ Meeting

Retrieved on: 
Friday, August 19, 2022

The consolidated financial statements for the group will be audited as soon as the individual component audits are completed.

Key Points: 
  • The consolidated financial statements for the group will be audited as soon as the individual component audits are completed.
  • The invitation for the AGM will be sent to shareholders as soon as the statutory audits are completed in Switzerland.
  • The AGM will be our first opportunity for a face-to-face meeting with our shareholders since the crisis triggered by the pandemic and we look forward to meeting with our shareholders to provide the financial statements and an update on our accomplishments and future outlook.
  • The forward-looking statements contained in this media release are based on the views and assumptions of Terraoil Swiss AG as of this date and Terraoil Swiss AG does not assume any obligation to update or revise this media release.

BMC ANNOUNCES CASH TENDER OFFER FOR UP TO $100 MILLION OF NOTES

Retrieved on: 
Wednesday, August 17, 2022

Holders must make their own decision as to whether to tender Notes and, if so, the principal amount of the Notes to tender.

Key Points: 
  • Holders must make their own decision as to whether to tender Notes and, if so, the principal amount of the Notes to tender.
  • Any tender of Notes for purchase pursuant to the Offer from a Holder that is unable to make these representations will not be accepted.
  • BMC works with 86% of the Forbes Global 50 and customers and partners around the world to create their future.
  • BMC, BMC Software, the BMC logo, and other BMC marks are the exclusive properties of BMC Software, Inc. and are registered or may be registered with the U.S. Patent and Trademark Office or in other countries.

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

Retrieved on: 
Monday, August 15, 2022

The aggregate gross proceeds from the offering were approximately $150 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Verona Pharma.

Key Points: 
  • The aggregate gross proceeds from the offering were approximately $150 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Verona Pharma.
  • All ADSs in the offering were offered by Verona Pharma.
  • Jefferies, Piper Sandler & Co. and Truist Securities acted as the book-running managers for the offering.
  • BTIG, H.C. Wainwright & Co. and Wedbush PacGrow acted as co-managers for the offering.

DGAP-News: Eleving Group S.A.: Unaudited 6M 2022 results on 15 August 2022 - Invitation to earnings call on 17 August 2022

Retrieved on: 
Thursday, August 11, 2022

Eleving Group and its group companies (the "Group"), specializing in vehicle and consumer financing, cordially invite investors and analysts to an earnings call with the Management Board on 17 August 2022, 15:00 CET, following the publication of its unaudited 6M 2022 results on 15 August 2022.

Key Points: 
  • Eleving Group and its group companies (the "Group"), specializing in vehicle and consumer financing, cordially invite investors and analysts to an earnings call with the Management Board on 17 August 2022, 15:00 CET, following the publication of its unaudited 6M 2022 results on 15 August 2022.
  • Group CEO Modestas Sudnius and CFO Maris Kreics will present and comment on the unaudited results by means of a presentation.
  • The presentation for the earnings call will be available here as of 16 August2022.
  • Eleving Group comprises a number of financial technology companies with a global presence.

Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering

Retrieved on: 
Thursday, August 11, 2022

LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the pricing of its upsized public offering of 12,400,000 American Depositary Shares (ADSs), each representing eight ordinary shares of Verona Pharma, nominal value 0.05 per share, at a price of $10.50 per ADS, for aggregate gross proceeds of $130.2 million before deducting underwriting discounts and commissions (the Offering).

Key Points: 
  • LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the pricing of its upsized public offering of 12,400,000 American Depositary Shares (ADSs), each representing eight ordinary shares of Verona Pharma, nominal value 0.05 per share, at a price of $10.50 per ADS, for aggregate gross proceeds of $130.2 million before deducting underwriting discounts and commissions (the Offering).
  • All ADSs in the Offering are being offered by Verona Pharma.
  • In addition, Verona Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,860,000 ADSs at the public offering price, less the underwriting discount and commission.
  • The Offering is expected to close on August 15, 2022, subject to the satisfaction of customary closing conditions.

Verona Pharma plc Announces Proposed Underwritten Public Offering

Retrieved on: 
Tuesday, August 9, 2022

LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares (ADSs), each representing eight ordinary shares of Verona Pharma, nominal value 0.05 per share (the Offering).

Key Points: 
  • LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares (ADSs), each representing eight ordinary shares of Verona Pharma, nominal value 0.05 per share (the Offering).
  • All ADSs in the Offering will be offered by Verona Pharma.
  • The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.
  • In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.

DGAP-News: SFC Energy AG: Capital increase successfully placed

Retrieved on: 
Thursday, July 28, 2022

The public offering in Germany will be made solely by means of, and on the basis of, a published securities prospectus.

Key Points: 
  • The public offering in Germany will be made solely by means of, and on the basis of, a published securities prospectus.
  • This announcement is not an offer of securities for sale in the United States.
  • Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.
  • All information presented or contained in this press release is subject to verification, correction, completion and change without notice.

TERRAOIL SWISS AG: Terraoil Announces Positive Developments on New Oilfield

Retrieved on: 
Monday, July 25, 2022

The Minister appointed a negotiation group to meet with Terraoil representatives and conclude the final terms of the Petroleum Agreement.

Key Points: 
  • The Minister appointed a negotiation group to meet with Terraoil representatives and conclude the final terms of the Petroleum Agreement.
  • This is a very positive development for the expansion of our business in Albania.
  • This media release serves informational purposes and constitutes neither an offer to sell nor a solicitation or an advertisement to buy any shares of Terraoil Swiss AG in any jurisdiction.
  • The forward-looking statements contained in this media release are based on the views and assumptions of Terraoil Swiss AG as of this date and Terraoil Swiss AG does not assume any obligation to update or revise this media release.